Nicotinamide riboside (NR) is one of the most heavily researched NAD+ precursors on the market, and also one of the most commonly overstated. The distinction that matters is between two separate questions: does NR raise NAD+ levels (yes, robustly), and does raising NAD+ levels this way produce a measurable health benefit (much less settled, and often no). Both parts of that answer are worth knowing before treating NR as a longevity ingredient.
What NR is and how the body uses it
NR is one of three vitamin B3-family precursors — alongside niacin (nicotinic acid) and nicotinamide (NAM) — that the body converts into NAD+ (nicotinamide adenine dinucleotide), the central redox coenzyme involved in cellular energy metabolism, DNA repair, and sirtuin-mediated processes linked to aging biology.1 NR follows its own distinct biosynthesis route (the salvage pathway) rather than the pathway used by niacin, which is part of why researchers became interested in it as a supplemental option separate from niacin and nicotinamide — both of which carry their own dose-limiting side effects (niacin's flushing response, nicotinamide's hepatotoxicity risk at high doses).12
NR is legally available in the EU as an authorized Novel Food ingredient — see our Novel Food explainer for the specific 2019 authorization, its 300 mg/day general-adult-population limit, and the pregnancy/breastfeeding restriction attached to it.
What's well established: NR reliably raises NAD+
The pharmacokinetic and NAD+-raising effect of NR is genuinely well documented. The first human pharmacokinetic trial found that single oral doses of 100, 300, and 1,000 mg of NR produced dose-dependent increases in the blood NAD+ metabolome.3 A more recent head-to-head human comparison (published in Nature Metabolism, January 2026) directly compared NR, NMN, and nicotinamide, and found that both NR and NMN roughly doubled circulating NAD+ levels after 14 days of supplementation, while nicotinamide only did so transiently, at the 4-hour mark.4 That same study identified a mechanistic detail worth noting: gut bacteria appear to convert both NMN and NR into nicotinic acid, which is itself a potent NAD+ booster — meaning at least part of NR's effect on blood NAD+ may run through a microbial intermediate step rather than direct absorption alone.4
Clinical trials have used a range of doses from 300 mg/day up to 2,000 mg/day, and have consistently shown NR to be safe and to raise NAD+ in whole blood, immune cells, urine, muscle, and even brain tissue.5
What's much less settled: does raising NAD+ actually improve health outcomes
This is the part of the NR story that gets left out of most marketing copy. A 2022 twin study — a genuinely strong design, since co-twins share genetics and much of their environment — gave 20 BMI-discordant twin pairs an escalating NR dose (250–1,000 mg/day) over 5 months and found real improvements in systemic NAD+ metabolism, muscle mitochondrial number, myoblast differentiation, and gut microbiota composition — but explicitly did not find improvement in adiposity or overall metabolic health.56 The study's own framing is blunt about this: most short-term human trials of NR have failed to show significant improvements in body composition or metabolic health in overweight or obese individuals, even though NAD+ levels reliably rise.5
A more targeted 2025 randomized controlled trial tested NR (2,000 mg/day) specifically in long-COVID patients over 24 weeks, evaluating cognitive symptoms and recovery alongside NAD+ levels — a genuinely different population and outcome set than general longevity marketing addresses, and one where the results speak to a specific clinical population, not a general “raises your energy” claim.78
Why this distinction matters for how NR should actually be marketed
NR does not currently carry any EFSA-authorized health claim — its Novel Food authorization covers safety and permitted dose, not a permitted benefit statement.9 That makes the honest framing straightforward: NR reliably does one well-documented thing (raises measurable NAD+ levels, with mechanistic and pharmacokinetic data to support it), and the leap from “raises NAD+” to “reverses aging,” “boosts energy,” or “improves metabolic health” is a leap the current clinical evidence mostly does not support — and in several well-designed studies, actively fails to support for metabolic outcomes specifically. The correct claim territory for NR right now is the biomarker itself (NAD+ elevation), described mechanistically, not the downstream health outcomes that remain an open research question.